{"id":27408,"date":"2020-09-16T10:33:19","date_gmt":"2020-09-16T08:33:19","guid":{"rendered":"https:\/\/kymos.com\/news\/partenaires-mondiaux-biopharmaceutiques\/"},"modified":"2020-09-16T10:33:19","modified_gmt":"2020-09-16T08:33:19","slug":"partenaires-mondiaux-biopharmaceutiques","status":"publish","type":"post","link":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/","title":{"rendered":"Partenaires mondiaux biopharmaceutiques"},"content":{"rendered":"

D\u00e9couvrez Pablo Cobo : expert reconnu de KYMOS en mati\u00e8re de d\u00e9veloppement de m\u00e9dicaments biologiques<\/strong><\/span><\/h3>\n
\n
\n
\n
\n

Pablo Cobo, notre responsable des essais biopharmaceutiques, dipl\u00f4m\u00e9 en chimie et pionnier des produits biologiques, se souvient de ses d\u00e9buts chez Ipsen, \u00e0 une \u00e9poque o\u00f9 le d\u00e9veloppement des produits peptidiques \u00e9tait bien diff\u00e9rent :<\/span><\/p>\n

\u00ab En 1994, les entreprises biopharmaceutiques r\u00e9alisaient la majeure partie de leur d\u00e9veloppement en interne, mais en raison des co\u00fbts \u00e9lev\u00e9s li\u00e9s au personnel sp\u00e9cialis\u00e9 et \u00e0 l\u2019instrumentation, elles ont commenc\u00e9 \u00e0 externaliser leurs activit\u00e9s de test aupr\u00e8s d\u2019organismes de recherche tiers \u00bb, explique M. Cobo. \u00ab Aujourd\u2019hui, gr\u00e2ce aux CRO et CDMO sp\u00e9cialis\u00e9es, les entreprises qui ne disposent pas des infrastructures n\u00e9cessaires peuvent d\u00e9velopper des produits biologiques et biosimilaires sp\u00e9cifiques de mani\u00e8re rentable. \u00bb <\/em><\/span><\/p>\n

D\u00e9fis actuels li\u00e9s aux essais de produits biopharmaceutiques <\/strong><\/span><\/p>\n

Le d\u00e9partement biopharmaceutique de KYMOS se concentre sur le contr\u00f4le qualit\u00e9 des produits biologiques innovants et des biosimilaires, les deux principaux segments de la biopharmacie. Or, la demande d’\u00e9tudes de comparabilit\u00e9 des biosimilaires a consid\u00e9rablement augment\u00e9 ces derni\u00e8res ann\u00e9es. Pablo Cobo a une hypoth\u00e8se pour expliquer ce ph\u00e9nom\u00e8ne : <\/span><\/p>\n

\u00ab \u00c0 l\u2019instar des g\u00e9n\u00e9riques dans les ann\u00e9es 80, de nombreux m\u00e9dicaments biopharmaceutiques \u00e0 succ\u00e8s voient leurs brevets expirer et sont d\u00e9sormais tr\u00e8s demand\u00e9s sous forme de biosimilaires. Nous collaborons actuellement avec des dizaines de biosimilaires et transf\u00e9rons des m\u00e9thodes de clients du monde entier : anticorps monoclonaux (AcM) d\u2019Asie, hormones recombinantes d\u2019Am\u00e9rique latine, facteurs de croissance d\u2019Europe\u2026 Travailler avec des biosimilaires et leurs produits biologiques de r\u00e9f\u00e9rence est complexe, car leur diversit\u00e9 est \u00e0 la hauteur de leur complexit\u00e9 mol\u00e9culaire, et r\u00e9aliser tous les tests n\u00e9cessaires \u00e0 leur caract\u00e9risation n\u2019est pas toujours la solution la plus efficace. Par cons\u00e9quent, les entreprises souhaitant se lancer sur le march\u00e9 des biosimilaires ont tendance \u00e0 externaliser plus fr\u00e9quemment leurs services d\u2019essais que ne le faisaient auparavant les fabricants de g\u00e9n\u00e9riques. \u00bb <\/em><\/span><\/p>\n

Cette tendance positive est si marqu\u00e9e que malgr\u00e9 l’\u00e9pid\u00e9mie de coronavirus, l’\u00e9quipe de Pablo a enregistr\u00e9 une augmentation de 2,5 fois de la demande de services et une hausse de 44 % de la valeur moyenne des devis approuv\u00e9s par rapport \u00e0 la m\u00eame p\u00e9riode en 2019.<\/span>
\n\u00ab Nous pr\u00e9voyons qu’\u00e0 moyen terme, les biosimilaires repr\u00e9senteront la plus grande part de l’activit\u00e9 de notre d\u00e9partement \u00bb,<\/em> conclut M. Cobo.<\/span><\/p>\n

Qu\u2019est-ce que l\u2019\u00e9quipe de tests biopharmaceutiques de KYMOS peut offrir de plus que les autres CRO ?<\/strong><\/span><\/p>\n

Pablo Cobo est fier de son \u00e9quipe d’experts form\u00e9s en interne et de ses installations bien \u00e9quip\u00e9es, mais il existe une autre raison importante pour laquelle nos clients choisissent KYMOS comme laboratoire de r\u00e9f\u00e9rence :<\/span><\/p>\n

\u00ab Nombre de nos clients viennent de pays comme la Chine, la Cor\u00e9e du Sud, Singapour, le Liban, l\u2019Inde ou l\u2019Argentine, o\u00f9 l\u2019on trouve d\u2019autres CRO et des r\u00e9glementations plus favorables aux entreprises \u00bb,<\/em> explique M. Cobo. \u00ab Cependant, tous les m\u00e9dicaments fabriqu\u00e9s hors UE\/EEE, y compris les produits biopharmaceutiques, doivent \u00eatre test\u00e9s par un laboratoire europ\u00e9en agr\u00e9\u00e9 avant leur mise sur le march\u00e9. Le fait que nous soyons \u00e9galement importateurs et fabricants agr\u00e9\u00e9s, capables de fournir des services d\u2019importation, de contr\u00f4le des lots et de lib\u00e9ration des lots par une personne qualifi\u00e9e (QP), facilite le transfert de leurs m\u00e9thodes de fabrication vers KYMOS pour ces entreprises : nous pouvons les accompagner tout au long du processus. \u00bb<\/em> <\/span><\/p>\n

Parmi ces clients internationaux figure CELLTRION, une entreprise sud-cor\u00e9enne de premier plan sp\u00e9cialis\u00e9e dans les anticorps monoclonaux biosimilaires et les produits biologiques innovants. Yong Suk Yang, responsable de l’\u00e9quipe mondiale des op\u00e9rations de contr\u00f4le qualit\u00e9 chez CELLTRION, partage son exp\u00e9rience de collaboration avec KYMOS : <\/span><\/p>\n

\u00ab Nous d\u00e9veloppons actuellement plusieurs nouveaux projets de biosimilaires en plus de notre produit phare Remsima (un biosimilaire de l’infliximab vendu sous le nom d’Inflectra aux \u00c9tats-Unis) et consid\u00e9rons KYMOS comme l’une des meilleures CRO en Europe pour la lib\u00e9ration et les essais de m\u00e9dicaments. \u00bb <\/em><\/span><\/p>\n

Pablo Cobo compl\u00e8te les propos de M. Yang en y apportant son point de vue personnel sur des projets ant\u00e9rieurs :<\/span><\/p>\n

\u00ab CELLTRION est une entreprise dot\u00e9e de m\u00e9thodes analytiques robustes et d’une connaissance approfondie de son portefeuille. Travailler pour elle a \u00e9t\u00e9 un v\u00e9ritable privil\u00e8ge, car cela nous a permis de mettre en \u0153uvre des techniques de caract\u00e9risation d’anticorps monoclonaux (mAb) performantes, telles que l’\u00e9lectrophor\u00e8se capillaire ou l’imagerie par focalisation iso\u00e9lectrique Protein Simple (iCE3). \u00bb<\/em> M. Cobo poursuit : \u00ab Je consid\u00e8re les projets de nos clients comme un v\u00e9ritable partenariat : nous les accompagnons dans tous leurs besoins en mati\u00e8re de contr\u00f4le qualit\u00e9 et acqu\u00e9rons, de ce fait, un savoir-faire pr\u00e9cieux. Apr\u00e8s de nombreuses ann\u00e9es d’essais de produits biologiques et biosimilaires innovants, notre exp\u00e9rience parle d’elle-m\u00eame. \u00bb<\/em><\/span><\/p>\n

perspectives d’avenir<\/strong><\/span>
\nEn 2012, le d\u00e9partement des essais biopharmaceutiques de KYMOS ne comptait que deux membres. Aujourd’hui, apr\u00e8s un d\u00e9m\u00e9nagement et deux agrandissements de laboratoire, l’\u00e9quipe de Pablo a d\u00e9cupl\u00e9 ses effectifs et b\u00e9n\u00e9ficie de perspectives de croissance optimistes, port\u00e9es par la tendance actuelle \u00e0 l’externalisation. La constance et la fiabilit\u00e9 de leur travail leur ont valu des retours positifs de clients du monde entier et ont permis \u00e0 KYMOS de se hisser parmi les 10 premiers fournisseurs mondiaux de services de biosimilaires<\/a><\/strong> . Fort de cette position enviable, que pourrait bien souhaiter de plus Pablo Cobo ? Sa r\u00e9ponse est imm\u00e9diate : <\/span><\/p>\n

\u00ab Un nouveau laboratoire ! Nous avons agrandi nos installations l’ann\u00e9e derni\u00e8re, mais nous manquons d\u00e9j\u00e0 d’espace ! \u00bb<\/em><\/span><\/p>\n

 <\/p>\n

Vous pouvez consulter ici plus d’informations sur les tests de biosimilaires<\/strong><\/a> de KYMOS ; la caract\u00e9risation des produits biologiques et biosimilaires<\/a><\/strong> et la bioanalyse des produits biologiques et biosimilaires<\/strong><\/a> ou nous contacter \u00e0 l’ adresse commercial@kymos.com<\/a> .<\/a><\/span><\/p>\n

CELLTRION est un acteur majeur de l’industrie pharmaceutique cor\u00e9enne. L’entreprise a lanc\u00e9 le premier biosimilaire d’anticorps au monde dans un pays au secteur pharmaceutique relativement peu d\u00e9velopp\u00e9 et ambitionne de devenir un acteur mondial de la biopharmacie gr\u00e2ce \u00e0 des approches novatrices dans le domaine des petites mol\u00e9cules et de nouveaux secteurs d’activit\u00e9, comme sa plateforme de sant\u00e9 connect\u00e9e. Pour plus d’informations sur CELLTRION, veuillez les contacter \u00e0 l’ adresse contact@celltrion.com<\/a> . <\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

D\u00e9couvrez Pablo Cobo : expert reconnu de KYMOS en mati\u00e8re de […]<\/p>\n","protected":false},"author":6,"featured_media":27410,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[260],"tags":[],"class_list":["post-27408","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-groupe-kymos"],"acf":[],"yoast_head":"\nPartenaires mondiaux biopharmaceutiques | Kymos<\/title>\n<meta name=\"description\" content=\"Pablo Cobo, responsable des tests biopharmaceutiques chez CELLTRION, partage son point de vue sur le march\u00e9 biopharmaceutique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Partenaires mondiaux biopharmaceutiques | Kymos\" \/>\n<meta property=\"og:description\" content=\"Pablo Cobo, responsable des tests biopharmaceutiques chez CELLTRION, partage son point de vue sur le march\u00e9 biopharmaceutique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-16T08:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"437\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"Partenaires mondiaux biopharmaceutiques\",\"datePublished\":\"2020-09-16T08:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/\"},\"wordCount\":1136,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"articleSection\":[\"Kymos Group\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/\",\"name\":\"Partenaires mondiaux biopharmaceutiques | Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"datePublished\":\"2020-09-16T08:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Pablo Cobo, responsable des tests biopharmaceutiques chez CELLTRION, partage son point de vue sur le march\u00e9 biopharmaceutique.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"width\":800,\"height\":437,\"caption\":\"Biopharmaceutical Global Partners\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/partenaires-mondiaux-biopharmaceutiques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Partenaires mondiaux biopharmaceutiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Partenaires mondiaux biopharmaceutiques | Kymos","description":"Pablo Cobo, responsable des tests biopharmaceutiques chez CELLTRION, partage son point de vue sur le march\u00e9 biopharmaceutique.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/","og_locale":"fr_FR","og_type":"article","og_title":"Partenaires mondiaux biopharmaceutiques | Kymos","og_description":"Pablo Cobo, responsable des tests biopharmaceutiques chez CELLTRION, partage son point de vue sur le march\u00e9 biopharmaceutique.","og_url":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/","og_site_name":"Kymos","article_published_time":"2020-09-16T08:33:19+00:00","og_image":[{"width":800,"height":437,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"\u00c9crit par":"Joan Puig de Dou","Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"Partenaires mondiaux biopharmaceutiques","datePublished":"2020-09-16T08:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/"},"wordCount":1136,"image":{"@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","articleSection":["Kymos Group"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/","url":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/","name":"Partenaires mondiaux biopharmaceutiques | Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","datePublished":"2020-09-16T08:33:19+00:00","author":{"@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Pablo Cobo, responsable des tests biopharmaceutiques chez CELLTRION, partage son point de vue sur le march\u00e9 biopharmaceutique.","breadcrumb":{"@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","width":800,"height":437,"caption":"Biopharmaceutical Global Partners"},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/fr\/news\/partenaires-mondiaux-biopharmaceutiques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Partenaires mondiaux biopharmaceutiques"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/fr\/#website","url":"https:\/\/kymos.com\/fr\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/fr\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/27408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/comments?post=27408"}],"version-history":[{"count":0,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/27408\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media\/27410"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media?parent=27408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/categories?post=27408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/tags?post=27408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}